全文获取类型
收费全文 | 49756篇 |
免费 | 3570篇 |
国内免费 | 1277篇 |
专业分类
耳鼻咽喉 | 175篇 |
儿科学 | 825篇 |
妇产科学 | 573篇 |
基础医学 | 3707篇 |
口腔科学 | 315篇 |
临床医学 | 4057篇 |
内科学 | 6577篇 |
皮肤病学 | 594篇 |
神经病学 | 2682篇 |
特种医学 | 1090篇 |
外科学 | 3016篇 |
综合类 | 6008篇 |
现状与发展 | 3篇 |
预防医学 | 5350篇 |
眼科学 | 331篇 |
药学 | 14273篇 |
18篇 | |
中国医学 | 1895篇 |
肿瘤学 | 3114篇 |
出版年
2024年 | 153篇 |
2023年 | 731篇 |
2022年 | 1637篇 |
2021年 | 1932篇 |
2020年 | 1592篇 |
2019年 | 1424篇 |
2018年 | 1449篇 |
2017年 | 1405篇 |
2016年 | 1535篇 |
2015年 | 1719篇 |
2014年 | 3277篇 |
2013年 | 4066篇 |
2012年 | 3221篇 |
2011年 | 3402篇 |
2010年 | 2595篇 |
2009年 | 2433篇 |
2008年 | 2471篇 |
2007年 | 2309篇 |
2006年 | 1996篇 |
2005年 | 1680篇 |
2004年 | 1361篇 |
2003年 | 1179篇 |
2002年 | 962篇 |
2001年 | 913篇 |
2000年 | 792篇 |
1999年 | 735篇 |
1998年 | 558篇 |
1997年 | 584篇 |
1996年 | 487篇 |
1995年 | 459篇 |
1994年 | 463篇 |
1993年 | 380篇 |
1992年 | 395篇 |
1991年 | 328篇 |
1990年 | 310篇 |
1989年 | 275篇 |
1988年 | 292篇 |
1987年 | 286篇 |
1986年 | 255篇 |
1985年 | 312篇 |
1984年 | 353篇 |
1983年 | 192篇 |
1982年 | 231篇 |
1981年 | 189篇 |
1980年 | 194篇 |
1979年 | 172篇 |
1978年 | 160篇 |
1977年 | 149篇 |
1976年 | 146篇 |
1975年 | 138篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine 总被引:1,自引:0,他引:1
L. C. Kirkwood R. L. Nation & A. A. Somogyi 《British journal of clinical pharmacology》1997,44(6):549-555
Aims Using human liver microsomes from donors of the CYP2D6 poor and extensive metabolizer genotypes, the role of individual cytochromes P-450 in the oxidative metabolism of dihydrocodeine was investigated.
Methods The kinetics of formation of N- and O -demethylated metabolites, nordihydrocodeine and dihydromorphine, were determined using microsomes from six extensive and one poor metabolizer and the effects of chemical inhibitors selective for individual P-450 enzymes of the 1A, 2A, 2C, 2D, 2E and 3A families and of LKM1 (anti-CYP2D6) antibodies were studied.
Results Nordihydrocodeine was the major metabolite in both poor and extensive metabolizers. Kinetic constants for N -demethylation derived from the single enzyme Michaelis-Menten model did not differ between the two groups. Troleandomycin and erythromycin selectively inhibited N -demethylation in both extensive and poor metabolizers. The CYP3A inducer, α-naphthoflavone, increased N -demethylation rates. The kinetics of formation of dihydromorphine in both groups were best described by a single enzyme Michaelis-Menten model although inhibition studies in extensive metabolizers suggested involvement of two enzymes with similar K m values. The kinetic constants for O -demethylation were significantly different in extensive and poor metabolizers. The extensive metabolizers had a mean intrinsic clearance to dihydromorphine more than ten times greater than the poor metabolizer. The CYP2D6 chemical inhibitors, quinidine and quinine, and LKM1 antibodies inhibited O -demethylation in extensive metabolizers; no effect was observed in microsomes from a poor metabolizer.
Conclusions CYP2D6 is the major enzyme mediating O -demethylation of dihydrocodeine to dihydromorphine. In contrast, nordihydrocodeine formation is predominantly catalysed by CYP3A. 相似文献
Methods The kinetics of formation of N- and O -demethylated metabolites, nordihydrocodeine and dihydromorphine, were determined using microsomes from six extensive and one poor metabolizer and the effects of chemical inhibitors selective for individual P-450 enzymes of the 1A, 2A, 2C, 2D, 2E and 3A families and of LKM1 (anti-CYP2D6) antibodies were studied.
Results Nordihydrocodeine was the major metabolite in both poor and extensive metabolizers. Kinetic constants for N -demethylation derived from the single enzyme Michaelis-Menten model did not differ between the two groups. Troleandomycin and erythromycin selectively inhibited N -demethylation in both extensive and poor metabolizers. The CYP3A inducer, α-naphthoflavone, increased N -demethylation rates. The kinetics of formation of dihydromorphine in both groups were best described by a single enzyme Michaelis-Menten model although inhibition studies in extensive metabolizers suggested involvement of two enzymes with similar K
Conclusions CYP2D6 is the major enzyme mediating O -demethylation of dihydrocodeine to dihydromorphine. In contrast, nordihydrocodeine formation is predominantly catalysed by CYP3A. 相似文献
62.
组织扩张术皮肤胶原的代谢改变 总被引:4,自引:0,他引:4
目的:研究常规扩张(ITE)和持续快速扩张(CTE)对皮肤胶原代谢的影响。方法用白色小家猪制作组织扩张术动物模型,用Gordeladze法测定血清和扩张组织的羟脯氨酸(HP)含量,藻酸盐印模材膜片法测量标记区面积;光镜测量真皮厚度。结果:ITE组血清HP含量升高,0.8倍,CTE组升高1.2倍,ITE和CTE组皮肤含量与正常皮肤相同,组织中HP总量均明显升高,持续扩张皮瓣组(CTEF)术后4wk皮 相似文献
63.
Such research evidence as exists on effective drug strategies in prevention and education draws attention to the importance of involving parents along with other community agencies and school governors. Much depends nevertheless on the way in which 'involvement' is interpreted and the assumptions that are made about parents' knowledge of drugs and drug education as well as their attitudes to drug issues. As the age of initial experimentation and contact with drugs continues to fall, the importance of enskilling parents to support drug education programmes for 5 year olds and upwards continues to rise. This paper reports the first wide ranging survey of parents' knowledge of drugs and drug issues across an entire English county embracing younger as well as older children. The need for more coordinated, informed and systematic guidance to parents is established. 相似文献
64.
The Problem of Intractability: The Continuing Need for New Medical Therapies in Epilepsy 总被引:7,自引:3,他引:4
Pierre Jallon 《Epilepsia》1997,38(S9):S37-S42
Summary: Treatment of epilepsy, one of the most common neurologic disorders, has evolved from "institutional" poly-therapy to "dogmatic" monotherapy, and, most recently, to "rational" polypharmacy. The introduction of bromides for the treatment of epilepsy was followed first by phenobarbital and then by phenytoin as therapeutic options. Although attempts to combine medications were legion, none was supported by studies that demonstrated the benefit of such combinations. The issue of adverse effects became a principal argument in favor of monotherapy. Monotherapy, using newly developed drugs, avoided problems due to drug interactions but was ineffective in 20–30% of patients. A greater understanding of basic disease mechanisms and developments in molecular biology have led to an increased number of effective drugs for the estimated 6–12% of patients with epilepsy whose condition is intractable. Clinical research continues to build on the work of basic scientists in attempting to develop treatments based on a desire to move beyond the palliative and to affect the causative mechanisms of the disease. Novel medical approaches now under exploration include the use of drugs with complementary mechanisms of action, stimulation of various components of the nervous system, biochemical manipulations, focal intracerebral drug perfusion, and gene therapy. 相似文献
65.
Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey 总被引:2,自引:1,他引:1
The behavioral effects of GBR 12909, a selective dopamine uptake inhibitor, were determined in squirrel monkeys trained to
respond under a fixed-interval (FI) schedule of stimulus termination and a second-order schedule of IV drug self-administration.
Intermediate doses of GBR 12909 increased FI response rate markedly, and the highest dose decreased response rate below control
values. The 5HT uptake inhibitors, alaproclate and fluoxetine, and the 5HT agonist, quipazine, attenuated the behavioral-stimulant
effects of GBR 12909, whereas the 5HT2A/2C antagonist, ritanserin, enhanced the behavioral-stimulant effects of the lowest dose. GBR 12909 reliably maintained self-administration,
and ritanserin increased response rate maintained by the highest dose. The dopamine agonist, quinpirole, increased FI response
rate in only one of three subjects, and ritanserin enhanced the behavioral-stimulant effects of quinpirole in that subject.
The dopamine agonist, apomorphine, only decreased FI response rate, and ritanserin did not alter its behavioral effects. The
pharmacological profile of GBR 12909 administered alone and in combination with selective 5HT drugs in the present study was
similar to that obtained previously with cocaine, further demonstrating that 5HT can reliably modulate the behavioral effects
of psychomotor stimulants with prominent dopaminergic actions.
Received: 9 July 1996 / Final version: 22 November 1996 相似文献
66.
R. Berkels A. Bertsch T. Zuther S. Dhein K. Stockklauser P. Rsen R. Rsen 《European journal of haematology》1997,58(5):307-313
Abstract: We tried to characterize the porcine platelet nitric oxide (NO) synthase and its L-arginine (L-arg)/NO metabolism. Using RT-PCR we could show a constitutive endothelial NOS (ecNOS) and an inducible NOS (iNOS) similar mRNA in platelets. The NOS protein could be evidenced by an ecNOS specific antibody which also bound in platelets. This finding could be confirmed by Western blot showing an ecNOS in the membrane but not the cytosolic fraction; iNOS protein could not be detected. Using NADPH-diaphorase staining we could show NO synthase in preactivated platelets but not in resting platelets, indicating that the platelet NOS may be activated during platelet activation/aggregation. Porcine L-arg plasma levels (9.31 × 10–5 mol/l ± 10%) could be shown to be in the same range as human plasma levels. Moreover, we could show that the NO precursor L-arg and hydroxy-L-arginine (OHarg) concentration dependently inhibited collagen induced platelet aggregation. Summarizing these results confirm the existence of and further characterize porcine platelet NO synthases. 相似文献
67.
Khema R. Sharma Jane Kent-Braun Mark A. Mynhier Michael W. Weiner Robert G. Miller 《Muscle & nerve》1995,18(12):1403-1411
The goals of this study were to investigate muscle fatigue in patients with multiple sclerosis (MS), and to determine the relationships between muscle fatigue, clinical status, and perceived fatigue. The fatigability of the anterior tibial muscle was quantitated in patients and controls during 9 min of intermittent stimulation (used to eliminate central sources of muscle fatigue). During exercise, the decline in tetanic force, phosphocreatine, and intracellular pH was greater in patients than in controls. The compound muscle action potential amplitude did not decrease during exercise, indicating that there was no failure of neuromuscular transmission during fatigue. Thus, the excessive fatigue in MS developed from sources beyond the muscle membrane. Following exercise, the recovery of tetanic force was delayed in patients (a pattern that suggests abnormal excitation–contraction coupling), whereas the recovery of metabolites was complete in both groups. Muscular fatigue was correlated with clinical disability but not with perceived fatigue. These results suggests that fatigue in MS has both central (perception, upper motor neuron dysfunction) and peripheral (impaired metabolism and excitation–contraction coupling) components.© 1995 John Wiley &Sons, Inc. 相似文献
68.
Neuropharmacology and Drug Interactions in Clinical Practice 总被引:2,自引:2,他引:0
Nina M. Graves 《Epilepsia》1995,36(S2):S27-S33
Summary: Absorption, distribution, and clearance are key pharmacokinetic principles. These parameters can be highly variable among patients and among compounds, and are factors that must be considered in the wide variability in response to medications. Current antiepileptic drugs (AEDs) present many challenges in their administration. However, understanding and utilizing pharmacokinetic principles can assist the clinician in the appropriate optimization of AEds. 相似文献
69.
HELEN J. GILL JAMES L. MAGGS STEPHEN MADDEN MUNIR PIRMOHAMED & B. KEVIN PARK 《British journal of clinical pharmacology》1996,42(3):347-353
1 Cytochrome P450-mediated bioactivation of sulphamethoxazole to a hydroxylamine has been implicated in the hypersensitivity reactions associated with co-trimoxazole administration. Inhibiting the formation of the hydroxylamine may be one method of preventing the high frequency of toxicity which is observed in HIV-infected patients. Therefore, in this study, we have investigated the ability of fluconazole and ketoconazole, known cytochrome P450 inhibitors, to inhibit the formation of sulphamethoxazole hydroxylamine.
2 Ten healthy male volunteers were given co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim) alone or 1 h after either fluconazole (150 mg) or ketoconazole (200 mg) in a randomized fashion with a washout period of at least 1 week between each phase. Urine was collected for 24 h, and sulphamethoxazole and its metabolites were quantified by electrospray LC-MS.
3 Ketoconazole had no effect on the urinary recovery of sulphamethoxazole or any of its metabolites. In contrast, fluconazole significantly ( P <0.001) inhibited the formation of sulphamethoxazole hydroxylamine by 50.0±15.1%. Fluconazole also inhibited the oxidation of sulphamethoxazole to the 5-methylhydroxy and 5-methylhydroxy acetate metabolites by 69.9±15.8% and 64.0±12.0%, respectively, but had no effect on the amount of sulphamethoxazole, N4 -acetyl sulphamethoxazole, or sulphamethoxazole N1 -glucuronide excreted in urine.
4 The potential clinical benefit of using fluconazole to prevent hypersensitivity to co-trimoxazole in patients with AIDS needs to be assessed in a prospective study using both metabolite formation and the clinical occurrence of adverse reactions as end-points. 相似文献
2 Ten healthy male volunteers were given co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim) alone or 1 h after either fluconazole (150 mg) or ketoconazole (200 mg) in a randomized fashion with a washout period of at least 1 week between each phase. Urine was collected for 24 h, and sulphamethoxazole and its metabolites were quantified by electrospray LC-MS.
3 Ketoconazole had no effect on the urinary recovery of sulphamethoxazole or any of its metabolites. In contrast, fluconazole significantly ( P <0.001) inhibited the formation of sulphamethoxazole hydroxylamine by 50.0±15.1%. Fluconazole also inhibited the oxidation of sulphamethoxazole to the 5-methylhydroxy and 5-methylhydroxy acetate metabolites by 69.9±15.8% and 64.0±12.0%, respectively, but had no effect on the amount of sulphamethoxazole, N
4 The potential clinical benefit of using fluconazole to prevent hypersensitivity to co-trimoxazole in patients with AIDS needs to be assessed in a prospective study using both metabolite formation and the clinical occurrence of adverse reactions as end-points. 相似文献
70.
在动物实验的基础上,比较了抗AFP单克隆抗体(mAb)和抗AFP多克隆抗体(pAb)两种不同抗体双弹头标记物在肝癌患者体内的生物代谢情况。结果显示,两种抗体标记物的血浆清除半衰期均在24h左右,mAb标记物的清除较pAb标记物略慢。尿清除的半衰期,mAb标记物约为120h,而pAb标记物则约为18h,表明二者的体内生物代谢不同,疗效可能不一。 相似文献